GeneTex
United States (US)

AChR alpha 4 (aa29-43) blocking peptide

Cat No. GTX31078-PEP

Application ELISA, Apuri, Blocking
Species Human
APPLICATION

Specificity/Sensitivity

The peptide was used in the production of GTX31078.
PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Region/Sequence

C-HVETRAHAEERLLKK

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

BFNC blocking peptide , EBN blocking peptide , EBN1 blocking peptide , NACHR blocking peptide , NACHRA4 blocking peptide , CHRNA4 blocking peptide , NACRA4 blocking peptide

Background

This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]

Research Area